Field Notes

Methods For Treatment Of Thyroid Cancer Treats the Relationship as the Point

An effort to spare patients thyroid surgery became a mature business, a patent weapon, and a lesson in diagnostic restraint.

Clay-diorama editorial illustration related to Methods For Treatment Of Thyroid Cancer.

What changes in this design

A reader might otherwise think that classifying a cancer means giving it a broad disease label. That view does not show how molecular information can be part of diagnostic work.

Here, molecular clues tied to gene activity are part of the work. They are used to make a profile, classify cancers including thyroid cancer, and analyze diagnostic results.

That is worth knowing because it tells you that the focus includes molecular profiling, cancer classification, and diagnostic analysis. The record does not state what is measured, which categories result, or what choices follow.

A biopsy that won't decide

Fine-needle aspiration can pull cells from a thyroid nodule and still leave the hardest question unanswered. That isn't easy. In the era that produced this patent family, up to one-third of those biopsies were indeterminate: not clearly benign and not clearly cancer. I understand why that uncertainty sends people toward an operating room. Surgery produces an answer, but it can also remove a thyroid that never needed to come out.

That human problem sits behind US20260253671A1, a new publication titled Methods For Treatment Of Thyroid Cancer. It matters. The filing describes molecular-profiling and diagnostic methods for genetic disorders and cancer: gene-expression product markers, cancer classification that includes thyroid cancer, molecular-profile determination, and analysis of diagnostic results. To me, this is evidence of a long effort to make an ambiguous needle sample actionable.

The test that bought time

May 7, 2009 is the date of the first provisional application. Everything starts there. By January 2011, Veracyte had launched Afirma to address the surgery-bound uncertainty. Its first Gene Expression Classifier reclassified about 52% of indeterminate nodules as benign. Reporting at the end of 2014 said the test had helped about 15,000 patients avoid surgery. For me, that claim is the best version of the case for molecular triage.

Eight years later, its newer test paired RNA whole-transcriptome sequencing with machine learning. The claim was striking. Veracyte reported 91% sensitivity, 68% specificity, and a 96% negative predictive value across 191 indeterminate nodules, plus 30% more benign calls than its predecessor. Those figures explain why clinicians would want the test. I don't think they settle what should happen to every person with a positive result.

A family from 2009

One earlier published continuation makes the treatment link unusually plain. Here, the idea turns clinical. In its independent first claim, US 2025/0034646 A1 starts with an indeterminate thyroid fine-needle aspiration. It calls for sequencing mRNA from at least two genes in a specified group, a computer classification that is positive for thyroid cancer, and then thyroidectomy, lobectomy, or radioactive iodine ablation. My reading is that classification stops being merely descriptive once it appears in a treatment claim.

Across the family, activity did not go dormant. Work continued. US 12,305,238, a related patent, issued on May 20, 2025. Veracyte reported 2025 Afirma revenue of $172.9 million from about 67,700 tests, an annual rise of 9%. Both facts point to a substantial business with modest growth. To me, this looks like a mature diagnostic franchise rather than a newly proved clinical idea.

Two tests in court

May 2025 brought a lawsuit that turned the family into an instrument of competition. Litigation changed the frame. According to the complaint, Veracyte sued Sonic, alleging that ThyroSeq v3 infringes three related patents; the complaint calls Afirma and ThyroSeq the major commercially available molecular tests for thyroid nodules. My caution is simple: those aren't court findings. Still, claims built around an indeterminate needle sample are now part of a fight over competing tests.

Viewed against the only head-to-head randomized trial on this question, the fight looks less dramatic. Results were close. Among 346 patients, diagnostic surgery was avoided in 51% with Afirma GSC and 49% with ThyroSeq v3. Specificity was 80% versus 85%, with P=.33, not a statistically significant difference. For me, that doesn't prove the tests are interchangeable for every patient. Instead, it is a reason to resist marketing-sized differences.

Where the risk actually sits

Risk isn't simply a false result. Decisions follow. What worries me is treating a test as if it settles the decision that follows. Evidence from a 61-patient real-world study showed that gene-expression testing reduced surgical recommendations, but the decline in actual surgeries was not statistically significant. Another study of 140 tested patients found that testing changed management in 7.9% of cases, and all but one of those 11 patients was overtreated relative to final pathology. This is, I think, the gap between recommendation, decision, and outcome that the patent family cannot solve.

Here's the wider warning. Thyroid-cancer screening in asymptomatic adults receives a Grade D recommendation from the U.S. Preventive Services Task Force, which cites overdiagnosis harms. Such guidance doesn't decide whether an indeterminate nodule deserves molecular testing. Screening and diagnosis are different jobs. But I think we should ask what each new classification buys before it carries someone toward surgery. A federal court's 2025 decision also left laboratory-developed tests such as Afirma under CLIA rather than device review by the federal regulator. Ultimately, I put the essential scrutiny in the clinic: evidence, consent, follow-up, and a clear explanation of what a result cannot decide.

Sources

Reporting for this piece drew on the published filing and the references below.

The record, briefly. US20260253671A1, “Methods For Treatment Of Thyroid Cancer” The publication describes compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including gene-expression product markers, cancer classification including thyroid cancer, molecular-profile determination, and diagnostic-result analysis.

Identity details. The saved title-page transcription needs review, so names are not repeated here. Check the official published title page.

More angles on this

Next Generation Prenatal Screening: A Probability Where a Verdict Was ExpectedAnother reading from the same G16B classification family, bioinformatics.
CPC G16B: BioinformaticsThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
CPC C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganismsThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
In-Memory Computation System Using A Segmented Memory Architecture With Marks a Pause Worth NoticingAnother reading from the neighbouring G06F classification family, electric digital data processing.
Why a Deliberately Weaker Signal Can Make a System More HonestAnother reading from the wider G11C classification family, static stores.

Read around this one:Public patent record USPTO published figure